The short version of circadian rhythm fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Pulmonary disease: Pathophysiology: Due to vascular congestion in the lung, the pulmonary artery (Figure 3) becomes dilated and can compress the aorta and the LRLN. Primary pulmonary hypertension Pulmonary emboli Malignancy (pulmonary, mediastinal) Autoimmune: Mixed connective tissue disease Notable case: A young female with a history of mixed connective tissue disease presented with hoarseness of voice and was found to have secondary pulmonary artery hypertension. This was causing right heart enlargement and therefore compression of the LRLN. Idiopathic
If a cleft palate is present, the repair normally takes place at 9–12 months old. Before surgery, a polysomnography with a palatal plate in place is needed. This may predict the postoperative situation and gives insight on the chance of the presence of sleep apnea (OSAS) after the operation. Hearing loss is treated by bone conduction amplification, speech therapy, and educational intervention to avoid language/speech problems. The bone-anchored hearing aid is an alternative for individuals with ear anomalies. Zygomatic and orbital reconstruction is performed when the cranio-orbitozygomatic bone is completely developed, usually at the age of 5–7 years. In children, an autologous bone graft is mostly used. In combination with this transplantation, lipofilling can be used in the periorbital area to get an optimal result of the reconstruction. Reconstruction of the lower eyelid coloboma includes the use of a myocutaneous flap, which is elevated and in this manner closes the eyelid defect. External ear reconstruction is usually done when the individual is at least eight years old. Sometimes, the external auditory canal or middle ear can also be treated. The optimal age for the maxillomandibular reconstruction is controversial; as of 2004, this classification has been used: Type I (mild) and Type IIa (moderate) 13–16 years Type IIb (moderate to severe malformation) at skeletal maturity Type III (severe) 6–10 years When the teeth are cutting, the teeth should be under supervision of an orthodontist to make sure no abnormalities occur.
== Hormone and Metabolic Modulators == Hormone and metabolic modulators modify the effects of hormones or accelerate or slow down enzyme reactions, for example anti-Estrogens are substances that block the effects of estrogen in the body (usually to prevent tumors) and are used by athletes to counter the side effects of steroids. Anti-estrogens are clinically used in the treatment of breast cancer and to reduce the breast cancer incidence in high-risk women. Examples of anti-estrogens and other hormone and metabolic modulators are: anastrozole, clomiphene, tamoxifen, raloxifene, and formestane.
== External links == Nigel Scrutton's University of Manchester official website Nigel Scrutton's research group website SYNBIOCHEM website Future Biomanufacturing Research Hub website C3 Biotechnologies Ltd official website
=== Notable cases === Dan Christensen, painter of abstract art. Died due to heart failure caused by polymyositis. Robert Erickson, American composer and teacher who was a leading modernist exponent of "12-tone" composition. Died from the effects of polymyositis. Ana Estrada, the first person in Peru to die by euthanasia on 21 April 2024, at the age of 47. David Lean, film director. Eric Samuelsen, playwright. Victor Manuel Resendiz Ruiz, wrestler. Cardinal John Wright Rosita Velazquez, Puerto Rican actress and singer.
Sources: en.wikipedia.org
Nitrogen is the most common pure element in the earth, making up 78.1% of the volume of the atmosphere (75.5% by mass), around 3.89 million gigatonnes (3.89×1018 kg). Despite this, it is not very abundant in Earth's crust, making up somewhere around 19 parts per million of this, on par with niobium, gallium, and lithium. (This represents 300,000 to a million gigatonnes of nitrogen, depending on the mass of the crust.) The only important nitrogen minerals are nitre (potassium nitrate, saltpetre) and soda nitre (sodium nitrate, Chilean saltpetre). However, these have not been an important source of nitrates since the 1920s, when the industrial synthesis of ammonia and nitric acid became common. Nitrogen compounds constantly interchange between the atmosphere and living organisms. Nitrogen must first be processed, or "fixed", into a plant-usable form, usually ammonia. Some nitrogen fixation is done by lightning strikes producing the nitrogen oxides, but most is done by diazotrophic bacteria through enzymes known as nitrogenases (although today industrial nitrogen fixation to ammonia is also significant). When the ammonia is taken up by plants, it is used to synthesise proteins. These plants are then digested by animals who use the nitrogen compounds to synthesise their proteins and excrete nitrogen-bearing waste. Finally, these organisms die and decompose, undergoing bacterial and environmental oxidation and denitrification, returning free dinitrogen to the atmosphere.
In 1998, at the 5th Conference of the Inter‑American Masonic Confederation (CMI) (Spanish: Confederación Masónica Interamericana), the 95 member bodies of CMI recognized the Grand Lodge of Cuba as "regular and correct," and rejected the regularity claims of the Grand Lodge of Cuba in Exile. In 2000, the Cuban government pressured the Grand Lodge of Cuba to elect a man named José Manuel Collera Venta as Grand Master. In 2005, when the Grand Lodge of Cuba attempted to expel Venta from Freemasonry "for an undisclosed reason," the Cuban government again intervened and stopped that from happening. By May 8, 2000, two factions existed within Cuban Freemasonry. One faction based in the National Temple headquarters preferred not to display any dissent against the government for the fear that their Lodges would be shuttered, but another faction within the leadership of the local Lodges advocated that Freemasons should be faithful to their statues, maintaining an impartial political position, no matter the consequences that might befall them. Lodges further away from Havana had more freedom due to less infiltration by government agents. In 2002, the Grand Lodge of Cuba reestablished its relationship with the Grand Lodge of Italy and the Grand Orient of Italy. By the year 2008, there were 29,110 Freemasons in Cuba, compared to 1980, when there were only 19,690.
=== Acute exacerbations === Acute exacerbations of IPF (AE-IPF) are defined as an unexplained worsening or development of dyspnea within 30 days with new radiological infiltrates at HRCT abnormality often superimposed on a background consistent with UIP pattern. The yearly incidence of AE-IPF is between 10 and 15% of all patients. The prognosis of AE-IPF is poor, with mortality ranging from 78% to 96%. Other causes of AE-IPF such as pulmonary embolism, congestive heart failure, pneumothorax, or infection need to be excluded. Pulmonary infection have to be ruled out by endotracheal aspirate or BAL. Many patients experiencing acute deterioration require intensive care treatment, particularly when respiratory failure is associated with hemodynamic instability, significant comorbidities or severe hypoxemia. However, mortality during hospitalization is high. Mechanical ventilation should be introduced only after carefully weighing the person's long-term prognosis and, whenever possible, the person's wishes. However, current guidelines discourage the use of mechanical ventilation in patients with respiratory failure secondary to IPF.
Small molecule targets Protein targets Cells and tissues Multiple rounds of selection and counter-selection are performed as part of each Optimer discovery process. Each discovery process can be adapted to include specific target, assay and buffer conditions to improve Optimer selection.
=== Burial in the Baháʼí Faith === In the Baháʼí Faith, burial law prescribes both the location of burial and burial practices and precludes cremation of the dead. It is forbidden to carry the body for more than one hour's journey from the place of death. Before interment the body should be wrapped in a shroud of silk or cotton, and a ring should be placed on its finger bearing the inscription "I came forth from God, and return unto Him, detached from all save Him, holding fast to His Name, the Merciful, the Compassionate". The coffin should be of crystal, stone or hard fine wood. Also, before interment, a specific Prayer for the Dead is ordained. The body should be placed with the feet facing the Qiblih. The formal prayer and the ring are meant to be used for those who have reached 15 years of age.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.